There are 2789 resources available
1480P - Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
Presenter: George Kim
Session: ePoster Display
1481P - Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status
Presenter: Jasmeet Kaur
Session: ePoster Display
1482P - Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients
Presenter: Roberto Borea
Session: ePoster Display
1550P - A post hoc analysis of the EPAZ trial: The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patients
Presenter: Rainer Hamacher
Session: ePoster Display
1551P - Efficacy of early phase trials for soft-tissue sarcoma patients: The Centre Léon Bérard and Gustave Roussy experience
Presenter: Elise Nassif
Session: ePoster Display
1552P - Magnitude of clinical benefit of cancer drugs used in advanced soft tissue sarcomas and GIST
Presenter: Raul Teres Lleida
Session: ePoster Display
1471P - Overall survival by BRCA and ATM mutation status in patients with metastatic pancreatic cancer: Findings from the PRIOR-2 study
Presenter: Gboyega Adeboyeje
Session: ePoster Display
1472P - Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
Presenter: Camille Evrard
Session: ePoster Display
1473P - Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort
Presenter: Esther Pijnappel
Session: ePoster Display
1364TiP - Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
Presenter: Byoung Chul Cho
Session: ePoster Display